These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24171773)

  • 1. From polypharmacology to target specificity: the case of PARP inhibitors.
    Liscio P; Camaioni E; Carotti A; Pellicciari R; Macchiarulo A
    Curr Top Med Chem; 2013; 13(23):2939-54. PubMed ID: 24171773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-Molecule Inhibitors of PARPs: From Tools for Investigating ADP-Ribosylation to Therapeutics.
    Kirby IT; Cohen MS
    Curr Top Microbiol Immunol; 2019; 420():211-231. PubMed ID: 30242511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose) polymerase inhibitors.
    Southan GJ; Szabó C
    Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP inhibitors: polypharmacology versus selective inhibition.
    Ekblad T; Camaioni E; Schüler H; Macchiarulo A
    FEBS J; 2013 Aug; 280(15):3563-75. PubMed ID: 23601167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural inhibitors of poly(ADP-ribose) polymerase-1.
    Banasik M; Stedeford T; Strosznajder RP
    Mol Neurobiol; 2012 Aug; 46(1):55-63. PubMed ID: 22476980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3.
    Lehtiö L; Jemth AS; Collins R; Loseva O; Johansson A; Markova N; Hammarström M; Flores A; Holmberg-Schiavone L; Weigelt J; Helleday T; Schüler H; Karlberg T
    J Med Chem; 2009 May; 52(9):3108-11. PubMed ID: 19354255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose)polymerase inhibition - where now?
    Woon EC; Threadgill MD
    Curr Med Chem; 2005; 12(20):2373-92. PubMed ID: 16181138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
    Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
    J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
    Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations.
    Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ
    Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying Direct Protein Targets of Poly-ADP-Ribose Polymerases (PARPs) Using Engineered PARP Variants-Orthogonal Nicotinamide Adenine Dinucleotide (NAD+) Analog Pairs.
    Carter-O'Connell I; Cohen MS
    Curr Protoc Chem Biol; 2015 Jun; 7(2):121-39. PubMed ID: 26344237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribose) polymerase as a key player in excitotoxicity and post-ischemic brain damage.
    Meli E; Pangallo M; Baronti R; Chiarugi A; Cozzi A; Pellegrini-Giampietro DE; Moroni F
    Toxicol Lett; 2003 Apr; 139(2-3):153-62. PubMed ID: 12628750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.
    Passeri D; Camaioni E; Liscio P; Sabbatini P; Ferri M; Carotti A; Giacchè N; Pellicciari R; Gioiello A; Macchiarulo A
    ChemMedChem; 2016 Jun; 11(12):1219-26. PubMed ID: 26424664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
    Papeo G; Forte B; Orsini P; Perrera C; Posteri H; Scolaro A; Montagnoli A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1377-400. PubMed ID: 19743897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
    Tiwari P; Khan H; Singh TG; Grewal AK
    Neurochem Res; 2022 Jul; 47(7):1830-1852. PubMed ID: 35437712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation.
    Lu AZ; Abo R; Ren Y; Gui B; Mo JR; Blackwell D; Wigle T; Keilhack H; Niepel M
    Biochem Pharmacol; 2019 Sep; 167():97-106. PubMed ID: 31075269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase.
    Menear KA; Adcock C; Alonso FC; Blackburn K; Copsey L; Drzewiecki J; Fundo A; Le Gall A; Gomez S; Javaid H; Lence CF; Martin NM; Mydlowski C; Smith GC
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3942-5. PubMed ID: 18579376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.
    Tentori L; Portarena I; Graziani G
    Pharmacol Res; 2002 Feb; 45(2):73-85. PubMed ID: 11846617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.